Repare Therapeutics Inc
NASDAQ:RPTX

Watchlist Manager
Repare Therapeutics Inc Logo
Repare Therapeutics Inc
NASDAQ:RPTX
Watchlist
Price: 3.495 USD -5.54% Market Closed
Market Cap: 148.3m USD
Have any thoughts about
Repare Therapeutics Inc?
Write Note

Intrinsic Value

RPTX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one RPTX stock under the Base Case scenario is 4.133 USD. Compared to the current market price of 3.495 USD, Repare Therapeutics Inc is Undervalued by 15%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

RPTX Intrinsic Value
4.133 USD
Undervaluation 15%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Repare Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for RPTX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about RPTX?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Repare Therapeutics Inc

Provide an overview of the primary business activities
of Repare Therapeutics Inc.

What unique competitive advantages
does Repare Therapeutics Inc hold over its rivals?

What risks and challenges
does Repare Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Repare Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Repare Therapeutics Inc.

Provide P/S
for Repare Therapeutics Inc.

Provide P/E
for Repare Therapeutics Inc.

Provide P/OCF
for Repare Therapeutics Inc.

Provide P/FCFE
for Repare Therapeutics Inc.

Provide P/B
for Repare Therapeutics Inc.

Provide EV/S
for Repare Therapeutics Inc.

Provide EV/GP
for Repare Therapeutics Inc.

Provide EV/EBITDA
for Repare Therapeutics Inc.

Provide EV/EBIT
for Repare Therapeutics Inc.

Provide EV/OCF
for Repare Therapeutics Inc.

Provide EV/FCFF
for Repare Therapeutics Inc.

Provide EV/IC
for Repare Therapeutics Inc.

Show me price targets
for Repare Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Repare Therapeutics Inc?

How accurate were the past Revenue estimates
for Repare Therapeutics Inc?

What are the Net Income projections
for Repare Therapeutics Inc?

How accurate were the past Net Income estimates
for Repare Therapeutics Inc?

What are the EPS projections
for Repare Therapeutics Inc?

How accurate were the past EPS estimates
for Repare Therapeutics Inc?

What are the EBIT projections
for Repare Therapeutics Inc?

How accurate were the past EBIT estimates
for Repare Therapeutics Inc?

Compare the revenue forecasts
for Repare Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Repare Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Repare Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Repare Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Repare Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Repare Therapeutics Inc with its peers.

Analyze the financial leverage
of Repare Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Repare Therapeutics Inc.

Provide ROE
for Repare Therapeutics Inc.

Provide ROA
for Repare Therapeutics Inc.

Provide ROIC
for Repare Therapeutics Inc.

Provide ROCE
for Repare Therapeutics Inc.

Provide Gross Margin
for Repare Therapeutics Inc.

Provide Operating Margin
for Repare Therapeutics Inc.

Provide Net Margin
for Repare Therapeutics Inc.

Provide FCF Margin
for Repare Therapeutics Inc.

Show all solvency ratios
for Repare Therapeutics Inc.

Provide D/E Ratio
for Repare Therapeutics Inc.

Provide D/A Ratio
for Repare Therapeutics Inc.

Provide Interest Coverage Ratio
for Repare Therapeutics Inc.

Provide Altman Z-Score Ratio
for Repare Therapeutics Inc.

Provide Quick Ratio
for Repare Therapeutics Inc.

Provide Current Ratio
for Repare Therapeutics Inc.

Provide Cash Ratio
for Repare Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Repare Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Repare Therapeutics Inc?

What is the current Free Cash Flow
of Repare Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Repare Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Repare Therapeutics Inc

Current Assets 243.7m
Cash & Short-Term Investments 223.6m
Receivables 15.3m
Other Current Assets 4.7m
Non-Current Assets 10.2m
PP&E 7.5m
Other Non-Current Assets 2.7m
Current Liabilities 39.1m
Accounts Payable 2.4m
Accrued Liabilities 26.3m
Other Current Liabilities 10.4m
Non-Current Liabilities 2.7m
Other Non-Current Liabilities 2.7m
Efficiency

Earnings Waterfall
Repare Therapeutics Inc

Revenue
51.1m USD
Operating Expenses
-167.4m USD
Operating Income
-116.2m USD
Other Expenses
22.4m USD
Net Income
-93.8m USD

Free Cash Flow Analysis
Repare Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

RPTX Profitability Score
Profitability Due Diligence

Repare Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Declining ROE
Negative Revenue Growth Forecast
Negative 1-Year Revenue Growth
19/100
Profitability
Score

Repare Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

RPTX Solvency Score
Solvency Due Diligence

Repare Therapeutics Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
65/100
Solvency
Score

Repare Therapeutics Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RPTX Price Targets Summary
Repare Therapeutics Inc

Wall Street analysts forecast RPTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RPTX is 13.989 USD with a low forecast of 8.08 USD and a high forecast of 26.25 USD.

Lowest
Price Target
8.08 USD
131% Upside
Average
Price Target
13.989 USD
300% Upside
Highest
Price Target
26.25 USD
651% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for RPTX?

Click here to dive deeper.

Dividends

Repare Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for RPTX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

RPTX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Repare Therapeutics Inc Logo
Repare Therapeutics Inc

Country

Canada

Industry

Biotechnology

Market Cap

147.4m USD

Dividend Yield

0%

Description

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company is headquartered in St-Laurent, Quebec and currently employs 152 full-time employees. The company went IPO on 2020-06-19. The firm is focused on the development of synthetic lethality (SL) based therapies to patients with cancer. The company uses genome wide, SNIPRx platform to systematically discover and develop targeted cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The firm is developing its pipeline of SL product candidates, including its lead product candidate, RP-3500, a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related (ATR) protein kinase for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated (ATM) kinase gene. Its preclinical programs include RP-6306 Protein Kinase Membrane-associated tYrosine- and Threonine- specific cdc-2 inhibitory (PKMYT1)kinase SL inhibitor, in advanced solid tumors.

Contact

QUEBEC
ST-LAURENT
7210 Frederick-Banting, Suite 100
+18574127018.0
www.reparerx.com

IPO

2020-06-19

Employees

152

Officers

President, CEO & Director
Mr. Lloyd Mitchell Segal
Executive VP & CFO
Mr. Steve Forte
Executive VP & Chief Medical Officer
Dr. Maria Koehler M.D., Ph.D.
Co-Founder
Dr. Agnel Sfeir Ph.D.
Executive VP & Chief Scientific Officer
Dr. Michael Zinda Ph.D.
Executive Vice President of Human Resource
Mr. Daniel Belanger
Show More
Executive Vice President of Discovery
Mr. Cameron Black Ph.D.
Executive VP, Chief Commercial & Portfolio Development Officer
Mr. Philip Herman
Show Less

See Also

Discover More
What is the Intrinsic Value of one RPTX stock?

The intrinsic value of one RPTX stock under the Base Case scenario is 4.133 USD.

Is RPTX stock undervalued or overvalued?

Compared to the current market price of 3.495 USD, Repare Therapeutics Inc is Undervalued by 15%.

Back to Top